Challenges in the multidisciplinary management of stage IV colon and rectal cancer

References

• Piso P, Arnold D. Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int 2011;108:802-8
   PubMed Web of Science ®Google Scholar
• Brücher BL, Piso P, Verwaal V, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC – overview and basics. Cancer Invest 2012;30:209-24
   PubMed Web of Science ®Google Scholar
• Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986;100:278-84
   PubMed Web of Science ®Google Scholar
• Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995;19:59-71
   PubMed Web of Science ®Google Scholar
• Fong Y, Fortner J, Sun LR, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer Ann Surg. 1999;3:309-21
   Google Scholar
• Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: a review and meta-analysis of prognostic factors. Clin Epidemiol 2012;4:283-301
   PubMedGoogle Scholar
• Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol 2011;2011:763245
   PubMedGoogle Scholar
• Kopetz S, Chang GJ, Overmann MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83
   PubMed Web of Science ®Google Scholar
• Folpreht G, Gruenberger T, Bechstein W, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/Cetuximab or FOLFIRI/Cetuximab in a multidisciplinary concept (CELIM-study). Ann Oncol 2014. [Epub ahead print]
   Google Scholar
• Montalti R, Berardi G, Laurent S, et al. Laparoscopic liver resection compared to open approach in patients with colorectal liver metastases improves further resectability: oncological outcomes of a case control matched-pairs analysis. Eur J Surg Oncol 2014;40:536-44
   PubMed Web of Science ®Google Scholar
• Karoui M, Penna C, Amin-Hashem M, et al. Indluences of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1-7
   PubMed Web of Science ®Google Scholar
• Narita M, Oussoultzoglou E, Fuchshuber P, et al. What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive properative chemotherapy? Ann Surg Oncol 2012;19:2526-38
   PubMed Web of Science ®Google Scholar
• Ammori JB, Kemeny NE, Fong Y, et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol 2013;20:2901-7
   PubMed Web of Science ®Google Scholar
• Loupakis F, Schirripa M, Caparello C, et al. Histopathologic evaluation of liver metastatses from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013;108:2549-56
   PubMed Web of Science ®Google Scholar
• Bischof DA, Clary BM, Maithel SK, et al. Surgical management of disappearing colorectal liver metastases. Br J Surg 2013;100:1414-20
   PubMed Web of Science ®Google Scholar
• Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008;247:49-57
   PubMed Web of Science ®Google Scholar
• Chua TC, Liauw W, Chu F, et al. Summary outomes of two-stage resection for advanced colorectal liver metastases. J Surg Oncol 2013;107:211-16
   PubMed Web of Science ®Google Scholar
• Donati M, Stavrou GA, Oldhafer KJ. Current position of ALPPS in the surgical landscape of CRLM treatment proposals. World J Gastroenterol 2013;19:6548-54
   PubMed Web of Science ®Google Scholar
• Oldhafer KJ, Lang H, Schlitt HJ, et al. Long-term experience after ex-situ liver surgery. Surgery 2000;127:520-7
   PubMed Web of Science ®Google Scholar
• Saied A, Katz SC, Espat NJ. Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases. Hepatobiliary Surg Nutr 2013;2:97-107
   PubMedGoogle Scholar
• Evrard S, Brouste V, McKelvie-Sebileau P, et al. Liver metastases in close contact to hepatic veins ablated under vascular exclusion. Eur J Surg Oncol 2013;39:1400-6
   PubMed Web of Science ®Google Scholar
• Lam VW, Laurence JM, Pang T, et al. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB (Oxford) 2014;16:101-8
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. Peritoperative FOLFOX4 chemotherpa and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983). long term results of a randomised controlled phase 3 trial. Lancet Oncol 2013;14:1208-15
   PubMed Web of Science ®Google Scholar
• Gallinger S, Biagi JJ, Fletcher GG, et al. Liver resection for colorectal metastases. Curr Oncol 2013;20:255-8
   Web of Science ®Google Scholar
• Maggiori L, Goere D, Viana B, et al. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. Ann Surg 2013;258:116-21
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild.type metastatic colorectal cancer German AIO study KRK 0306 FIRE3. J Clin Oncol 2013;31(Suppl):abstract LBA3506
   Google Scholar
• Ceelen WP, Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 2009;10:72-9
   PubMed Web of Science ®Google Scholar
• Russell AH, Tong D, Dawson LE, Wisbeck W. Adenocarcinoma of the proximal colon. Sites of initial dissemination and patterns of recurrence following surgery alone. Cancer 1984;53:360-7
   PubMed Web of Science ®Google Scholar
• Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465-72
   PubMedGoogle Scholar
• Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-63
   PubMed Web of Science ®Google Scholar
• Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:1330-6
   PubMed Web of Science ®Google Scholar
• Cashin PH, Graf W, Nygren P, Mahteme H. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2013;20:4183-9
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359-74
   PubMedGoogle Scholar
• Stewart JH4th, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005;12:765-77
   PubMed Web of Science ®Google Scholar
• Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263-7
   PubMed Web of Science ®Google Scholar
• Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 2012;38:617-23
   PubMed Web of Science ®Google Scholar
• Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681-5
   PubMed Web of Science ®Google Scholar
• Lee DH, Oh SY, Lee YR, et al. A phase II study of modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis. Cancer Res Treat 2011;43:225-30
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29-42
   PubMed Web of Science ®Google Scholar
• Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006;93:100-4
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124-32
   PubMed Web of Science ®Google Scholar
• Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63-8
   PubMed Web of Science ®Google Scholar
• Esquivel J, Averbach A, Chua TC. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg 2011;253:764-8
   PubMed Web of Science ®Google Scholar
• Esquivel J, Averbach A. Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin. Gastroenterol Res Pract 2012;2012:981245
   PubMed Web of Science ®Google Scholar
• Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128-33
   PubMed Web of Science ®Google Scholar
• Kianmanesh R, Scaringi S, Sabate JM, et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg 2007;245:597-603
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Zhao J, Morris DL. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. Eur J Surg Oncol 2009;35:1299-305
   PubMed Web of Science ®Google Scholar
• Allard MA, Adam R, Ruiz A, et al. Is unexpected peritoneal carcinomatosis still a contraindication for resection of colorectal liver metastases? Combined resection of colorectal liver metastases with peritoneal deposits discovered intra-operatively. Eur J Surg Oncol 2013;39:981-7
   PubMed Web of Science ®Google Scholar
• Glockzin G, Renner P, Popp FC, et al. Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2011;18:1052-9
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426-32
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-43
   PubMed Web of Science ®Google Scholar
• Hompes D, D’Hoore A, Van Cutsem E, et al. The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: a Belgian Multicentre Prospective Phase II Clinical Study. Ann Surg Oncol 2012;19:2186-94
   PubMed Web of Science ®Google Scholar
• Quenet F, Goere D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 2011;254:294-301
   PubMed Web of Science ®Google Scholar
• Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 2013;257:1065-71
   PubMed Web of Science ®Google Scholar
• Hompes D, D’Hoore A, Wolthuis A, et al. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol 2013; Epub ahead print
   PubMed Web of Science ®Google Scholar
• Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. J Surg Oncol 2013;107:574-8
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 2009;249:900-7
   PubMed Web of Science ®Google Scholar
• Shen P, Thai K, Stewart JH, et al. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol 2008;15:3422-32
   PubMed Web of Science ®Google Scholar
• Glehen O, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747-54
   PubMed Web of Science ®Google Scholar
• Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg 2012;256:125-9
   PubMed Web of Science ®Google Scholar
• Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol 2014;21(8):2608-14
   PubMed Web of Science ®Google Scholar
• Glockzin G, Rochon J, Arnold D, et al. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer 2013;13:67
   PubMed Web of Science ®Google Scholar
• Piso P, Glockzin G, von Breitenbuch P, et al. Patient selection for a curative approach to carcinomatosis. Cancer J 2009;15:236-42
   PubMed Web of Science ®Google Scholar
• Pox C, Aretz S, Bischoff SC, et al. S3-Guideline Colorectal Cancer Version 1.0 Z Gastroenterol. 2013;51:753-854
   Google Scholar